Organic Active Ingredients TRIZ Cases

Combining nifedipine with a PGF2α receptor antagonist delays labor onset through synergistic uterine relaxation.

Compounds targeting BRG1 and BRM proteins treat disorders where prior therapies failed to modulate BAF complex activity effectively.

A block copolymer carrier uses a cationic segment to bind siRNA and a hydrophilic chain to shield the complex.

Allele-specific siRNAs selectively suppress mutant ACVR1 expression, reducing heterotopic ossification in Fibrodysplasia Ossificans Progressiva.

Amorphous perindopril sodium salt formulation uses sodium hydrogen carbonate to prevent ester hydrolysis and maintain pharmaceutical stability.

Antisense oligonucleotides cleave MAPT pre-mRNA via nuclease recruitment, reducing Tau expression to treat neurodegenerative disorders.

Segmented lacosamide dosage form reduces peak-trough fluctuations and adverse reactions by maintaining stable therapeutic blood levels for 24 hours.

A dual drug portion system segments lidocaine salt and base into separate housings within a single elastic tube, enabling precise control over release kinetics.

Dual-acting fused gamma-carbolines bypass ketamine side effects by activating mTOR pathways for immediate depression relief.

Roseoflavin and trametinib target the riboflavin pathway to overcome ineffective conventional treatments for pancreatic cancer.

Formula I alkylated piperazine compounds inhibit Bruton's tyrosine kinase to treat autoimmune diseases and cancers.

Bivalent compounds conjugate a CBP P300 ligand to a degradation tag, inducing targeted protein breakdown via ubiquitin ligase recruitment.

Combining oral paracetamol with topical diclofenac emulgel targets pain and inflammation through complementary mechanisms.

Bacterial metabolite-derived ALPK1 agonists resolve treatment reliability gaps by inducing targeted immune activation and synergistic anti-tumor effects.

Amino acid combination with hyaluronic acid modulates gene expression to accelerate wound healing in oral mucositis.

CD73 inhibitors block enzymatic activity to reduce adenosine, reversing immunosuppression and sensitizing tumors to therapy.

Local quality and asymmetry design enable selective inhibition of FABP5 and FABP7, increasing extracellular anandamide levels for targeted pain relief.

Form-P crystallization of Erlotinib hydrochloride using methylene chloride and dry HCl gas eliminates hazardous solvents while ensuring thermodynamic stability.

2,4-disubstituted pyrimidine compounds inhibit protein kinases through irreversible covalent bonding to cysteine residues in the kinase domain.

PAC-1 analogues chelate labile zinc to activate procaspase-3, overcoming resistance in cancers with elevated enzyme levels.

Processing bioabsorbable polymer-drug solutions through solvent evaporation maintains drug integrity while enabling high loading capacity.

Porphyrin-phospholipid nanovesicles resolve stability versus control contradictions by using NIR-triggered phase transitions for precise drug delivery.

Formula I compounds inhibit BET family bromodomains, addressing the need for effective inhibitors across multiple disease indications.

Combines Andrographis, Astragalus, Eleuthero, Isatis, Lomatium, Pelargonium, Sambucus, Scute, and Zinc to inhibit viral reproduction.

Formula I compounds inhibit eIF4A activity, resolving the trade-off between specific cancer pathway targeting and off-target translation effects.

Abasic antisense oligomers modulate splicing precision in intron 1, resolving insufficient modulation of conventional sequences.

Engineered HNF4A mRNA variants achieve higher expression levels and longer-lasting activity to treat liver diseases like fibrosis and cirrhosis.

Adding methionine and antioxidants prevents light-induced oxidation, maintaining immunoconjugate stability without complex formulation changes.

GalNAc conjugates direct siRNA to hepatocytes via receptor binding, resolving systemic delivery specificity issues.

Dry granulation eliminates sulfurous odor in high-dose N-acetylcysteine tablets, reducing size and excipient load.

Short surfactant peptides self-assemble into nanospheric structures for therapeutic delivery.

Segmented enteric-coated microgranules suspended in triglyceride esters prevent acid degradation and extend shelf life beyond one month.

N-methylalaninyl maytansinol linkers resist endosomal oxidation while enabling protease cleavage for targeted drug release.

Glucose oxidase enzyme combined with dietary fibers and polyols manages blood sugar levels while providing a safe, sugar-like taste.

Antisense oligomers target C6 mRNA to suppress protein expression, blocking membrane attack complex formation that inhibits nerve regeneration.

Structural modifications to the maytansinoid core enhance ADC stability and potency while reducing non-specific toxicity.

Bisulfite agents convert insoluble beta-lapachone into soluble hydroxy sulfonate derivatives, resolving low solubility and enhancing bioavailability.

Isthmin-1 protein activates PI3K/AKT signaling to increase adipose glucose uptake while suppressing hepatic lipid synthesis.

Low-temperature reaction with organic solvents produces high-purity ferric citrate hydrate, reducing secondary impurities that cause peptic ulcers.

Segmenting AMPA receptors via TARP γ8 binding reduces sedation and ataxia side effects while maintaining anti-convulsant activity.

Targeting ribose-5-phosphate isomerase A via RNAi overcomes chemoresistance and inhibits migration in solid tumors.

Formula I dimers inhibit NFkB nuclear translocation, resolving toxicity trade-offs while maintaining therapeutic efficacy.

Combined sEH inhibition and ER stress reduction modulates epoxy fatty acid levels to treat neuropathic pain.

Ovatodiolide targets E6 and E7 proteins to induce selective apoptosis in HPV-positive cancer cells while sparing healthy primary tissues.

Novel pyridine derivatives combine phosphodiesterase 4 inhibition with muscarinic M3 antagonism to deliver bronchodilation and anti-inflammatory effects.

Sulfoximine glycosidase inhibitors resolve non-specific enzyme inhibition by targeting O-GlcNAcase, improving brain penetration for Alzheimer's treatment.

Combining HDAC6 and PD-L1 inhibitors reduces adverse effects from pan-HDAC inhibition while arresting cancer cell growth.

Tetrahydroxylated derivatives bypass defective BSEP transporters to restore bile secretion in cholestatic patients.

Segmented impeller fins apply localized mechanical force to delump APIs while maintaining crystallinity and lattice water specifications.

Dehydrating Formula I compounds with trifluoromethanesulfonic anhydride forms pyrano-[2,3-c]pyridine derivatives.

Azolecarboxamide compounds inhibit TrkA receptors to treat overactive bladder and interstitial cystitis without anticholinergic side effects.

Breath figure technique creates porous therapeutic films enabling controlled drug release profiles.

Substituted resorcyclic acid compounds activate AMPK via mitochondrial perturbations, bypassing difficult dietary restriction regimes.

Substituted pyrazolopyrimidines act as positive allosteric modulators on the GABA-B receptor to enhance endogenous ligand efficacy.

Formula I compounds inhibit BACE-1, renin, and plasmepsins to halt disease progression while reducing drug development complexity.

Hydroxyquinoline-sensitized europium chelates emit luminescence at 616 nm to detect kinase activity without background fluorescence interference.

Folate-coated nanoparticles bind folate receptors on cancer cells to deliver cytotoxic agents, reducing systemic toxicity to healthy tissues.

Self-immolative moieties enable rapid drug release after PSA cleavage, bypassing enzymatic steps that reduce efficacy and cause safety issues.

Peptide compounds inhibit the hepatitis C virus NS3 protease to reduce viral load and address sustained reduction limitations in current therapies.

Telescoped dehydroxyamination consolidates quinoline synthesis steps, reducing process time from 27 hours to 6 hours and increasing yield above 59 percent.

Formula I compounds modulate RORγ activity to address inadequate treatment availability for autoimmune and inflammatory conditions.

Administering less than 2.0 MIU/m2/day of IL-2 reduces toxicity while improving T cell survival.

Novel imipridone derivatives featuring 3,5-disubstituted benzyl groups demonstrate strong cytotoxicity against cancer cells.

Buffering ingredients modify gastrointestinal pH to prevent rapid absorption and euphoric effects from excessive doses.

A two-step process converts 2-furoic acid esters to symmetrically substituted intermediates for high-yield production.

A 3 mg sumatriptan subcutaneous injection delivers optimized plasma profiles through controlled osmolality.

Neuroactive steroids treat treatment-emergent sexual dysfunction caused by antidepressants without compromising therapeutic efficacy.

5-(4-pyridyloxy)pyrazole compounds inhibit TGF-βR1 kinase to address the lack of effective solid tumor treatments.

Silicasomes neutralize acidic lysosomal pH and trigger endoplasmic reticulum stress to overcome the immune-suppressive tumor microenvironment.

Dry co-grinding a ternary composition of CoQ10, HPC carriers, and sucrose esters increases solubility without thermal degradation or solvent use.

Anti-ILT7 antibodies deplete plasmacytoid dendritic cells to lower type I interferon signaling, addressing side effects from broad immunosuppression.

Substituted pyrido[3,4-d]pyrimidin-4-one compounds inhibit histone demethylase enzymes to treat cancer and neoplastic diseases.

Combining EGFR, MEK, and CDK inhibitors overcomes single-agent resistance while significantly increasing cancer cell-killing efficiency.

Gm-Cn lipid particles deliver p53-encoding mRNA to restore tumor suppressor function in cancer cells with mutated genes.

Formula I compounds inhibit FGFR kinases, resolving insufficient inhibition effectiveness in current cancer therapies.

Targeting peptides conjugated to drug carriers resolve the contradiction between therapeutic efficacy and cellular specificity in prostate cancer treatment.

Novel monomethyl fumarate prodrug compounds synthesized through ester condensation with 4-hydroxybenzyl alcohol derivatives enhance oral absorption and bioavailability.

Selective MKK4 inhibitors resolve non-selective kinase inhibition trade-offs to promote liver regeneration.

A glyceryl monocaprylocaprate sub-coating prevents eutectic melting and color changes in ibuprofen and paracetamol tablets.

Magnesium trisilicate neutralizes gastric acid while alginic acid creates a buoyant foam barrier, eliminating aluminum intoxication and constipation risks.

Oral ketamine compositions resolve the contradiction between rapid onset and high IV costs by enabling stable, cost-effective home treatment.

Agar and hydroxypropyl starch create a stable jelly that prevents sedimentation and eliminates powdery aftertaste for easier ingestion.

Chia seed and bee pollen biscuit delivers medication via indentation, resolving the trade-off between supplement nutrition and convenient pill administration.

Double negative T cells eliminate chemotherapy-resistant leukemic stem cells to prevent relapse and extend disease-free survival.

Engineered rAAV vectors utilize RNA interference to knock down myotilin expression, addressing inadequate treatments for Limb Girdle Muscular Dystrophy Type 1A.

Water-soluble carriers solubilize lipophilic cannabinoids, preventing recrystallization and enhancing bioavailability.

Targeting PCSK9 expression reduces adverse side effects from broad immunosuppressants while treating psoriasis and metabolic disorders.

Conjugating therapeutic peptides with bone-targeting moieties extends half-life, reduces dosing frequency, and prevents bone loss.

Isoxazole derivatives modulate 5-HT2A serotonin receptor activity, resolving stability and pharmacokinetic trade-offs for coronary artery disease treatment.